LivaNova (NASDAQ:LIVN - Free Report) had its price target trimmed by Needham & Company LLC from $75.00 to $64.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Several other research firms have also issued reports on LIVN. Robert W. Baird upped their price target on LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, October 31st. StockNews.com upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 14th. Finally, Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LivaNova presently has a consensus rating of "Buy" and a consensus price target of $64.20.
Get Our Latest Report on LIVN
LivaNova Stock Up 1.7 %
Shares of LIVN traded up $0.70 during trading on Wednesday, reaching $41.63. The company's stock had a trading volume of 807,916 shares, compared to its average volume of 582,675. The company has a fifty day moving average of $47.40 and a two-hundred day moving average of $49.49. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47. The company has a market cap of $2.26 billion, a price-to-earnings ratio of 99.12 and a beta of 1.00. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.
Insider Transactions at LivaNova
In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company's stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.27% of the company's stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of LivaNova by 1.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company's stock valued at $780,000 after purchasing an additional 289 shares during the last quarter. Atria Investments Inc lifted its holdings in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock valued at $297,000 after purchasing an additional 331 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in shares of LivaNova by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock valued at $328,000 after purchasing an additional 425 shares during the last quarter. Finally, Xponance Inc. lifted its holdings in shares of LivaNova by 6.1% during the fourth quarter. Xponance Inc. now owns 7,762 shares of the company's stock valued at $359,000 after purchasing an additional 445 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
